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Translational Relevance
MET oncogene is an emerging molecular target for NSCLC. Multiple mechanisms contribute to MET activation. The incidence and clinicopathological characteristics of tumors with MET alterations are yet to be established. This study represents the first comprehensive parallel screening of MET alterations including MET∆14 mutation, DNA copy number alteration and protein expression in a large cohort of NSCLC. Oncogenic MET∆14 mutation and high-level amplification (MET/CEP7 ratio ≥5), which are mutually exclusive to other major driver mutations, MET is a high affinity receptor tyrosine kinase that could initiate an array of pathways promoting cell proliferation, survival and metastasis upon stimulation.
Gain of function alterations of MET by DNA amplification, mutation and protein over-expression are driver events of oncogenesis in many cancer types.
Dysregulation of MET enhances the malignant properties and predict poor prognosis that represents a possible target for personalized therapy (3) driver and a valid clinical target (5, 6) . MET mutations affecting exon 14 splicing elements occur in up to 5% of lung adenocarcinoma. These mutations result in a juxtamembrane domain lacking MET protein (MET∆14) with extended half-life after HGF stimulation that has been considered an oncogenic driver event. In vitro and in vivo studies have demonstrated that tumors harboring MET exon 14 mutation responded to MET inhibitors (1, 7, 8) . Clinical response to MET inhibitors in patients with MET∆14+ lung adenocarcinoma has been reported (9), further supporting MET as a novel therapeutic target. However, a recent phase III randomized clinical trial failed to demonstrate additional benefit of onartuzumab, an anti-MET monoclonal antibody, on advanced stage NSCLC patients treated with erlotinib whose tumors were identified as MET-positive by immunohistochemistry (10) . This underscores the importance of appropriate predictive biomarker for patient stratification in the new era of personalized medicine.
We have reported the driver mutation profile of 154 lung adenocarcinoma and adenosquamous cell carcinoma and demonstrated that MET DNA alterations defined a subgroup of patients with aggressive diseases that might potentially benefit from anti-MET targeted therapy (11) . The clinical implication of MET alterations in different histological subsets of NSCLC remains undefined. In the current study, we aimed to determine the prevalence of MET DNA alterations, including exon 14 skipping mutations (MET∆14) and amplifications, in a large cohort of Chinese patients, and define the clinicopathological characteristics of MET-positive tumors.
Materials and Methods

Patients and samples
Patients with primary NSCLC who underwent surgical resection at Prince of adenocarcinoma and adenosquamous cell carcinoma has been reported in a previous study (11) .
Construction of tissue microarray (TMA)
Tissue microarrays were constructed using a tissue arrayer (Beecher Instruments, Silver Spring, MD). 
Immunohistochemistry (IHC)
Immunohistochemistry was carried out using Benchmark XT autostainer (Ventana, Tucson, AZ) using Ultraview detection system. MET IHC was performed using Confirm anti-Total c-MET (SP44) rabbit monoclonal antibody (Ventana, Tucson, AZ) according to manufacturer's instruction. Expression level of MET protein was determined by a scoring system considering both staining intensity and prevalence of intensities in tumor cells. The four staining score were defined as following: 3+ (≥ 50% of tumor cells staining with strong intensity); 2+ (≥ 50% of tumor cells with moderate or higher staining but < 50% with strong intensity); 1+ (≥ 50% of tumor cells with weak or higher staining but < 50% with moderate or higher intensity); or 0 (no staining or < 50% of tumor cells with any intensity) (12) . Tumors with moderate to strong MET protein expression (score 2+ and 3+) were considered IHC positive, while score 0 and 1+ were regarded as IHC negative for MET expression.
Mutational analysis
DNA was extracted from formalin-fixed paraffin-embedded (FFPE) tissue using QIAamp DNA mini kit (QIANGEN, Valencia, CA) according to manufacturer protocol. Manual microdissection was performed to ensure more than 70% tumor content in each DNA sample for subsequent analysis. Sanger sequencing was performed to screen for MET exon 14 splice site mutations.
Fluorescent in situ Hybridization (FISH)
MET gene copy number/ amplification status were investigated by MET/ CEP7 FISH probe (Abbott Molecular, IL) as reported previously (11) . Copy number per cell and MET/CEP7 ratio were counted in at least 50 non-overlapping tumor cell 
Screening for major driver events
EGFR exons 18-21, KRAS exons 2 and 3 were screened by PCR-direct sequencing.
ALK and ROS1 translocations were examined by dual color break apart FISH analysis as described previously (11) .
Statistical Analysis
Statistical analysis was performed using SPSS 19.0 (IBM Corp., Armonk, NY). 
Results
Patient characteristics
A total of 687 treatment naive NSCLC, comprising 392 (57.1%) adenocarcinoma (AD), 180 (26.2%) squamous cell carcinoma (SCC), 45 (6.6%) large cell carcinoma (LCC), 21 (3.1%) adenosquamous cell carcinoma (ADSQ), 27 (3.9%) lymphoepithelioma-like carcinoma (LELC) and 22 (3.2%) pulmonary sarcomatoid carcinoma (PSC) were recruited. The median age of the patients was 66 years (range 27 to 94 years) and male to female ratio was 2.1:1. Ever-smokers represented 63.9% of all patients and were more common in SCC than other histologies (p<0.001). AD was more common in female (p<0.001) and never-smokers (p<0.001). LELC occurred more frequently in female (p=0.043), never-smokers (p=0.004), and younger patients (p=0.005). The demographic information was shown in Supplementary Table 1. Major driver events including EGFR, KRAS, ALK and ROS1 were found in 26.2%, 8.9%, 3.9% and 1.5% of NSCLC, respectively. The mutation rate of the above mentioned genes were 41.6%, 12%, 6.1% and 2.3%, respectively in adenocarcinoma (Figure 1 ). EGFR mutation rate was significantly higher in adenocarcinoma (p<0.001), female (p<0.001) and never smokers (p<0.001). Significantly higher KRAS mutation rate was found in adenocarcinoma (p=0.001), male (p=0.012) and ever smokers (p=0.012). ALK translocation was more frequently detected in adenocarcinoma (p=0.001), advanced stage (p=0.012), never smokers (p=0.021), younger age (p<0.001) and smaller tumor size (p=0.001). ROS1 translocation was detected in 10 cases which associated with adenocarcinoma (p=0.049), advanced stage (p=0.001) and younger age (p=0.002). Table 1 summarized the clinicopathological associations of the driver events.
MET∆14 mutations in NSCLC
Research. By PCR-direct sequencing, 18 (2.6%) NSCLCs harboring mutations that disrupt the consensus sequences for MET exon 14 splicing sites were identified. The MET∆14 mutation rates were 2.6% in AD, 4.8% in ADSQ and 31.8% in PSC. No MET∆14 mutation was found in SCC, LCC, and LELC. A significantly higher MET∆14 mutation rate was found in pulmonary sarcomatoid carcinoma (p<0.001).
The mean age of MET∆14-positive patients was 73.7 years versus 64.2 years in MET∆14 negative patients (p=0.001). There were no significant differences in gender distribution, smoking history or stage between patients with or without MET∆14 mutation (Table 1) .
MET∆14 mutations were comprised point mutations (n=8) and small deletions (n=2) affecting the consensus sequence of the splice donor site elements, point mutation (n=1) and small deletions (n=4) affecting the splice acceptor sites, point mutation at branching point (n=1) and small deletions (n=2) disrupting the polypyrimidine tract at intron 13 ( Figure 2A 
MET gene copy number alteration (CNA)
FISH analysis was performed to investigate the CNA of MET gene in NSCLC.
Since there is no consensus scoring system for MET CNA, we employed three different scoring systems for MET FISH analysis as described in methodology. The results from the original scoring systems were summarized in Supplementary Table 3 ).
There was a significant association between MET∆14 mutation and MET CNA (p<0.001). Among 29 FISH+ cases, 20.7% (6/29) showed MET∆14 mutation (Supplementary Table 4 Notably, H-Amp coexisted with MET∆14 only and was mutually exclusive of other driver genes (Supplementary Table 4 ). 
MET protein expression in NSCLC
Survival analysis
The median follow-up time was 31.6 months (range 0.5 to 207.8 months).
Univariable analysis revealed that advanced pathological stage (p<0.001), ever-smoking history (p=0.04), presence of nodal metastasis (p<0.001), larger tumor size (p=0.002), MET∆14 mutation (p=0.043), high-level MET amplification (p<0.001) and EGFR mutation (p=0.015) associated with shorter overall disease specific survival (Table 3) . Representative Kaplan-Meier curves using the log-rank test showing the overall survival of all NSCLC patients were showed in Figure 3 . independent poor prognostic factors (Table 3) .
Discussion
MET DNA alterations including MET∆14 mutations and MET amplification are therapeutic relevant recurrent events. The clinicopathological characteristics, ethnic distribution and prognostic implications of MET∆14 mutations and MET amplification in treatment naive NSCLC are yet to be defined. Furthermore, most studies were conducted in Caucasian populations (1, 7, (17) (18) (19) (20) and data concerning MET DNA alterations in Asian is scanty (8, 21, 22) . To our knowledge, current study represents the largest cohort for the parallel assessment of MET∆14 mutations, MET copy number and protein expression in NSCLC.
Since there is no consensus in MET FISH scoring, we adopted three commonly keeping with previous report demonstrating MET amplification was not mutually exclusive to EGFR/KRAS mutations in treatment-naïve patients and thus did not fulfill the criteria of oncogenic driver (23) . However, we found that high-level MET amplification (MET/CEP7 ratio ≥5) was mutually exclusive to the major driver events in RTK/RAS/PI3K axis except MET∆14. Our data showed a significant association between MET DNA copy number alterations and MET∆14 mutation.
Such observations have been reported in EGFR, KRAS and other oncogenes that activation mutations positively correlated with gene copy number though the underlying mechanisms remain to be elucidated. Mutant allele specific imbalance of oncogenes has been noted in human cancers (24) . Although activating in one single allele of an oncogene is believed to be sufficient to drive tumorigenesis, concurrent mutation and copy number gain are frequently found in tumors harboring mutations.
These genetic alterations may have synergistic effect playing a greater role in development and maintenance of malignant phenotype. Though occurred in a low frequency, high-level amplification associated with strong MET protein expression and poorer prognosis. We further demonstrated that high-level amplification was an independent prognostic factor by multivariable analysis. Our result suggested that high-level amplifications (MET/CEP7 ratio ≥5) might be a good criterion that defines a molecular subset with poorer prognosis and potentially benefit from MET inhibitors.
MET exon 14 skipping mutations are not common but have been reported in diverse cancer types including lung cancer, glioblastoma multiforme, head and neck SCC as well as in cancer cell lines H596 (lung ADSQ) (7), Hs746T (gastric cancer) (25) and HCC2218 (breast cancer) (26) . Although MET∆14 mutations are less common than EGFR and KRAS, it has been detected in up to 5% of lung adenocarcinoma, a figure that is comparable to ALK translocations. This represents an additional target with proven sensitivity towards MET monoclonal antibody METMab (7) and MET TKIs (crizotinib and carbozantinib) (9, 17, 19) . Given the high prevalence NSCLC worldwide, anti-MET targeted therapy could potentially benefit thousands of patients each year.
The incidences of MET∆14 mutation and MET H-Amp were 2.6% and 1.0% respectively in lung adenocarcinoma, and 2.6% and 1.2% in NSCLC. The mutation rates are comparable with previous reports (1, (7) (8) (9) (20) (21) (22) and no significant ethnic difference across East Asian and Caucasian was found. MET∆14 mutation was not found in SCC (n=180) in the current study. Surprisingly, we found a significantly higher frequency of MET∆14 mutation in PSC (31.8%) compared with other histologic subtypes. This is the first study parallel comparing MET status across different histologic subtypes of NSCLC and demonstrating high MET∆14+ in PSC.
We also found frequent high-level MET amplification in PSC (13.6%). The result is in keeping with recent studies showing frequent MET alterations in PSC (16, 27) . Research. Figure 1 Research. 
